NXTC
Bylaws amended to allow arbitrary director changes
NeoGenomics amended its bylaws to allow electing up to 11 directors and altering their number by one per year, contingent on shareholder approval.
NXTC news
Latest 4 stories · newest Oct 5, 2026
NXTC
Company commences review of strategic alternatives
NEXT-ChemX Corporation announced it has formed a special committee to evaluate potential strategic alternatives to enhance shareholder value. Market relevance is high, as this often signals a potential sale, merger, or major restructuring.
NXTC
NXTC
NextCure presents positive Phase 1 data for SIM0505 in gynecologic cancers
NextCure announced 55% objective response rate for SIM0505 in gynecologic cancers at ASCO 2026, with favorable safety in heavily pretreated patients. The data supports continued dose optimization and potential advancement toward pivotal trials for this CDH6-targeting antibody drug conjugate.
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.
The same NXTC feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/NXTC/newsSTART FREE